Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Low-dose oral minoxidil alone is effective for treating hair loss, but combining it with dutasteride or finasteride may offer better results.

This study found that patients with rheumatoid arthritis taking tofacitinib had higher rates of serious adverse events compared to those with alopecia areata, highlighting the need for careful assessment when using it off-label for alopecia areata.

This case report presented a female with PCOS treated with metformin who developed hyperuricemia, migraine, neurological and joint pain, and rheumatic fever, later showing a delayed hypersensitivity reaction to benzathine benzyl penicillin treatment.

This analysis reports no significant differences between spironolactone and metformin for managing PCOS, noting spironolactone remains a potential off-label option for patients unable to use hormonal contraceptives, but larger studies are necessary to confirm its efficacy.

Low-dose oral minoxidil may be a promising alternative to topical minoxidil for hair loss.

In this study, researchers conducted additional IHC staining on equine skin sections and found that collagen type III primarily labels the extracellular matrix, while anti-PDGFR-antibody staining highlights cells with long-shaped processes mainly arranged around hair follicles.

This study discusses the prevalence and ethical considerations of off-label drug use in dermatology, emphasizing differing perspectives on informed consent between patients and physicians.

Dutasteride is more effective than finasteride for hair growth, and sublingual apomorphine quickly improves Parkinson's symptoms.

This review discusses clinical features, differential diagnosis, and treatments for female pattern hair loss, emphasizing the use of 2% topical Minoxidil and exploring alternative off-label therapies.

This review explores recent advancements in precise cell manipulation technologies, detailing the status, principles, benefits, limitations, and future potential of methods like single-cell manipulation and 3D bioprinting for cells and tissue engineering.

This case report observed a 5.5-year-old girl with Ectodermal Dysplasia-Syndactyly Syndrome 1, who experienced improved hair density and thickness with topical minoxidil and tretinoin, suggesting a potential adjunctive role for topical retinoids, though confirmation in larger studies is needed.

Pharmacists play a crucial role in patient care and education.

This pilot study employed in-vivo multiphoton microscopy to visualize pigment-producing melanocytes in vitiligo patients, aiming to enhance understanding of treatment impacts and potentially improve transplantation therapies.

Lgr5 is a marker for active, long-lasting stem cells in mouse hair follicles.

This review noted that alopecia areata is an autoimmune disease impacting hair follicles and offered insights into its complex pathogenesis involving immune responses, while highlighting ongoing research into new treatments such as Janus kinase inhibitors and other immunomodulatory drugs.

Testosterone replacement can help menopausal women with various symptoms, but should be used carefully and is not yet officially licensed in the UK for women.

This study found that disrupting Smad4 signaling in young mice led to overactivation of follicle stem cells, causing hyperplasia and depletion of the stem cell niche.

This study found that finasteride was associated with more reproductive adverse effects, including sexual dysfunction in men and fetal harm in women, compared to minoxidil in reported alopecia cases.

This study generated a Dct-H2BGFP mouse model that allows for effective identification and isolation of melanocytic cells in vivo, facilitating research into their molecular and biological properties.

This study expands the Drug Ontology to include therapeutic indications for resistant hypertension, malaria, and opioid abuse research, providing a framework for additional drug use representations beyond their original design.

The EADV Task Force on Hair Diseases reviewed existing literature and clinical experience to propose diagnostic and therapeutic recommendations for managing folliculitis decalvans, highlighting oral antibiotics, glucocorticosteroids, isotretinoin, and various systemic and topical therapies as key options for managing inflammation and preventing further hair loss.

Off-label drug use can be risky and requires careful consideration to ensure patient safety.

This study found that SESA oil significantly improved hair and scalp ailments more than coconut oil, with no adverse reactions reported during the study period.

This review discusses pharmacological treatments for pattern hair loss, focusing on minoxidil and finasteride's safety and efficacy, and reports no new clinical results.

This abstract provides no research findings; it is just information about the JAMA Dermatology journal's website and access options.

This study examined the safety and efficacy of dupilumab in adolescents with moderate-to-severe atopic dermatitis, finding that it was well tolerated and significantly improved symptoms over 52 weeks, with its safety profile similar to that in adults.

This chapter reviews current and emerging pharmacological treatments for alopecia, noting that the FDA's classification of alopecia as a cosmetic disease has limited drug development and led to off-label use of potentially dangerous compounds.

This pilot study found that using skin patting with iontophoresis to deliver dutasteride gel significantly improved hair density, shaft diameter, and pull test scores in men and postmenopausal women with treatment-resistant androgenetic alopecia, with participants reporting high satisfaction and no adverse events.

The study has limitations, and future research should use better methods to improve treatment for children with hair loss.

This review examines male androgenetic alopecia and reports no new clinical results, offering insights to aid dermatologists in making informed therapeutic decisions.